Qiming, Hillhouse bet on Jacobio's nascent pipeline of first-in-class drug hopefuls in $55M round
Qiming Capital and Hillhouse Capital are betting on a Chinese biotech to deliver world-class innovation in their latest investment.
Aside from the two prominent VCs …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.